ly 353381 has been researched along with Local Neoplasm Recurrence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bloss, J; Buller, R; Burke, T; Fowler, J; Gordon, A; McMeekin, DS; Melemed, A; Sabbatini, P | 1 |
| Booser, D; Buzdar, A; Dhingra, K; Enas, N; Hudis, C; Major, M; Melemed, A; Münster, PN; Ni, L; Norton, L; Seidman, A; Theriault, R | 1 |
2 trial(s) available for ly 353381 and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Selective Estrogen Receptor Modulators; Thiophenes | 2003 |
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.
Topics: Actuarial Analysis; Adult; Aged; Breast Neoplasms; Dose-Response Relationship, Drug; Endometrium; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Thiophenes | 2001 |